Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 300

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Proton-driven transformable nanovaccine for cancer immunotherapy

Open access
Gong, Ningqiang, Zhang, Yuxuan, Teng, Xucong, Wang, Yongchao, Huo, Shuaidong, Qing, Guangchao, Ni, Qiankun, Li, Xianlei, Wang, Jinjin, Ye, Xiaoxia, Zhang, Tingbin, Chen, Shizhu, Wang, Yongji, Yu, Jie, Wang, Paul C., Gan, Yaling, Zhang, Jinchao, Mitchell, Michael J., Li, Jinghong, Liang, Xing-Jie·2020·Nature Nanotechnology

Abstract

Cancer vaccines hold great promise for improved cancer treatment. However, endosomal trapping and low immunogenicity of tumour antigens usually limit the efficiency of vaccination strategies. Here, we present a proton-driven nanotransformer-based vaccine, comprising a polymer–peptide conjugate-based nanotransformer and loaded antigenic peptide. The nanotransformer-based vaccine induces a strong immune response without substantial systemic toxicity. In the acidic endosomal environment, the nanotransformer-based vaccine undergoes a dramatic morphological change from nanospheres (about 100 nanometres in diameter) into nanosheets (several micrometres in length or width), which mechanically disrupts the endosomal membrane and directly delivers the antigenic peptide into the cytoplasm. The re-assembled nanosheets also boost tumour immunity via activation of specific inflammation pathways. The nanotransformer-based vaccine effectively inhibits tumour growth in the B16F10-OVA and human papilloma virus-E6/E7 tumour models in mice. Moreover, combining the nanotransformer-based vaccine with anti-PD-L1 antibodies results in over 83 days of survival and in about half of the mice produces complete tumour regression in the B16F10 model. This proton-driven transformable nanovaccine offers a robust and safe strategy for cancer immunotherapy. A shape-changing pH-responsive cancer vaccine delivers antigenic peptides directly to the cytoplasm and boosts the cellular immune response upon activation of the inflammasome pathway, efficiently inhibiting tumour growth and extending survival in animal tumour models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41565-020-00782-3

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 300

Metadata

Authors
Gong, N., Zhang, Y., Teng, X., Wang, Y., Huo, S., Qing, G., Ni, Q., Li, X., Wang, J., Ye, X., Zhang, T., Chen, S., Wang, Y., Yu, J., Wang, P. C., Gan, Y., Zhang, J., Mitchell, M. J., Li, J., & Liang, X.-J.
Venue
Nature Nanotechnology
Published
2020-10-26
Volume
15
Issue
12
Pages
1053-1064
ISSN
  • 1748-3387 (ISSN-L)
  • 1748-3395
OpenAlex
W3094151083
Cited by
300
References
54
FWCI
12.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proton-driven transformable nanovaccine for cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41565-020-00782-3
The paper
Gong, N., Zhang, Y., Teng, X., Wang, Y., Huo, S., Qing, G., Ni, Q., Li, X., Wang, J., Ye, X., Zhang, T., Chen, S., Wang, Y., Yu, J., Wang, P. C., Gan, Y., Zhang, J., Mitchell, M. J., Li, J., & Liang, X.-J. (2020). Proton-driven transformable nanovaccine for cancer immunotherapy. Nature Nanotechnology. https://doi.org/10.1038/s41565-020-00782-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.